Marker Therapeutics Inc (MRKR) concluded trading on Thursday at a closing price of $1.92, with 62.72 million shares of worth about $120.43 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -24.41% during that period and on July 17, 2025 the price saw a gain of about 20.00%. Currently the company’s common shares owned by public are about 11.21M shares, out of which, 7.90M shares are available for trading.
Stock saw a price change of 6.67% in past 5 days and over the past one month there was a price change of 26.32%. Year-to-date (YTD), MRKR shares are showing a performance of -65.53% which decreased to -38.26% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.95 but also hit the highest price of $5.99 during that period. The average intraday trading volume for Marker Therapeutics Inc shares is 117.42K. The stock is currently trading 21.67% above its 20-day simple moving average (SMA20), while that difference is up 33.57% for SMA50 and it goes to -13.06% lower than SMA200.
Marker Therapeutics Inc (NASDAQ: MRKR) currently have 11.21M outstanding shares and institutions hold larger chunk of about 17.29% of that.
The stock has a current market capitalization of $21.72M and its 3Y-monthly beta is at 1.46. It has posted earnings per share of -$1.33 in the same period. It has Quick Ratio of 6.79 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MRKR, volatility over the week remained 35.69% while standing at 13.32% over the month.
Stock’s fiscal year EPS is expected to drop by -32.35% while it is estimated to decrease by -13.02% in next year. EPS is likely to shrink at an annualized rate of 7.40% for next 5-years, compared to annual growth of 23.96% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Canaccord Genuity on March 05, 2025 offering a Buy rating for the stock and assigned a target price of $8 to it. Coverage by Piper Sandler stated Marker Therapeutics Inc (MRKR) stock as an Overweight in their note to investors on March 25, 2021, suggesting a price target of $6 for the stock. On March 19, 2021, Cantor Fitzgerald Initiated their recommendations, while on May 12, 2020, Piper Sandler Downgrade their ratings for the stock with a price target of $2.50. Stock get a Buy rating from ROTH Capital on May 30, 2019.
